Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Ovarian Neoplasms 4Neoplasms 3Breast Neoplasms 3Recurrence 2Hypersensitivity 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoadjuvant Therapy 1Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 340Cisplatin 238Paclitaxel 203Radiotherapy 195Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 141Erlotinib Hydrochloride 107Etoposide 99Magnetic Resonance Spectroscopy 93Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 72durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49atezolizumab 42Irinotecan 42Radiation 40Topotecan 39Biopsy 39Standard of Care 38Cyclophosphamide 38Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × Poly(ADP-ribose) Polymerase Inhibitors × Clear all
NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
52 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡